DGAP-Ad-hoc: M1 Kliniken AG / Key word(s): Investment/Investment 
M1 Kliniken AG disposes subsidiary 'M1 Aesthetics GmbH' to HAEMATO AG - 
Transfer of the holding of the company within the scope of a capital 
increase in kind of HAEMATO AG 
 
15-Dec-2020 / 15:00 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation 
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
*M1 Kliniken AG disposes subsidiary "M1 Aesthetics GmbH" to HAEMATO AG - 
Transfer of the holding of the company within the scope of a capital 
increase in kind of HAEMATO AG* 
 
Berlin, 15.12.2020 - M1 Kliniken AG and HAEMATO AG today signed a contract 
for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 
Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the 
scope of a capital increase through contribution in kind. For this purpose, 
the Management Board of HAEMATO AG decided today with the approval of the 
Supervisory Board to increase the company's share capital by EUR 2,467,201 
to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a 
capital increase against contribution in kind under exclusion of the 
subscription right of the shareholders by using the existing authorised 
capital. The new shares will be subscribed and taken over exclusively by M1 
Kliniken AG. The transaction will be implemented with effect from 1.01.2021. 
After completion of the transaction, M1 Kliniken AG will hold a total of 
75.8% of the share capital of HAEMATO AG. 
 
M1 Aesthetics GmbH was valued on the basis of an IDW-S1 expert opinion with 
an enterprise value of a good &euro 58 million. The new HAEMATO shares were 
issued at a reference price of &euro23.55 per share, which corresponds to 
the volume-weighted average price of HAEMATO AG in the Xetra trading system 
in the period from 27.11.2020 to 9.12.2020. 
 
In 2019 M1 Aesthetics GmbH reported sales of about 51 million Euro and an 
EBIT of almost 7 million Euro. For 2020, M1 Aesthetics GmbH is expecting 
sales of a good EUR 30 million and an EBIT of approximately EUR 4 million - 
also due to corona effects, among other things. A further increase in 
earnings is expected in the coming years. 
 
*About M1 Kliniken AG* 
M1 Kliniken AG is the leading provider of beauty medical health services in 
Germany. In the aesthetic and surgical field, the group offers products and 
services of the highest quality standards. Under the brand "M1 Med Beauty", 
beauty medical treatments are currently offered at more than 35 specialist 
centres. With six operating theatres and 35 beds, the M1 Schlossklinik für 
plastische und ästhetische Chirurgie in Berlin is one of the largest and 
most modern facilities of its kind in Europe. Since the end of 2018, M1 has 
been driving forward its internationalisation and is currently also active 
in Austria, Switzerland, the Netherlands, England and Australia. 
 
Contact: 
M1 Kliniken AG 
Dr. Walter von Horstig, Management Board 
Grünauer Straße 5 
12557 Berlin 
Telefon: +49 (0)30 347 47 44 14 
E-Mail: ir@m1-kliniken.de 
 
15-Dec-2020 CET/CEST The DGAP Distribution Services include Regulatory 
Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     M1 Kliniken AG 
             Grünauer Straße 5 
             12557 Berlin 
             Germany 
Phone:       +49 (0)30 347 47 44 14 
Fax:         +49 (0)30 347 47 44 17 
E-mail:      ir@m1-kliniken.de 
Internet:    https://www.m1-kliniken.de 
ISIN:        DE000A0STSQ8 
WKN:         A0STSQ 
Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt 
             (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate 
             Exchange 
EQS News ID: 1155296 
 
End of Announcement DGAP News Service 
 
1155296 15-Dec-2020 CET/CEST

(END) Dow Jones Newswires

December 15, 2020 09:00 ET (14:00 GMT)